Longeveron

Update in progress

LGVN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Longeveron Inc. is a clinical‑stage biotechnology company focused on cellular therapies for aging‑related and life‑threatening conditions in the United States. Its lead product, LOMECEL‑B, is an allogeneic mesenchymal stem cell formulation derived from healthy young donor bone marrow. It is in Phase 3 for hypoplastic left heart syndrome, with prior Phase 2a data in Alzheimer’s disease and Phase 2b for aging frailty. Founded in 2014 and based in Miami, Florida.

Company score

Sentiment: 0.36; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.31; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive